Physician profile
Jonaid Aslam
NPI 1861653156
$1,199.71
in general payments reported to CMS, 2019-2025
17 companies · $801 in 2025
The $801 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $152 · 2020: $54.79 · 2022: $20.59 · 2023: $28.18 · 2024: $144 · 2025: $801.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $972.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $972.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $209.85 | 2020-2025 | Fasenra, Tezspire, Breztri |
| Glaxosmithkline, LLC. | $136.19 | 2019-2025 | Trelegy Ellipta, Nucala |
| Boehringer Ingelheim Pharmaceuticals, INC. | $126.77 | 2019-2025 | Ofev, Stiolto Respimat |
| Phathom Pharmaceuticals, INC. | $124.74 | 2024 | Voquezna |
| Takeda Pharmaceuticals U.S.A., INC. | $95.54 | 2025 | Aralast |
| Genzyme Corporation | $91.98 | 2019-2025 | |
| Madrigal Pharmaceuticals | $79.17 | 2025 | Rezdiffra |
| Insmed, INC. | $61.22 | 2025 | Brinsupri, Arikayce |
| Philips North America LLC | $53.43 | 2025 | Vest Therapy Und |
| Actelion Pharmaceuticals US, INC. | $44.03 | 2025 | Opsumit, Uptravi |
| Axsome Therapeutics, INC. | $41.95 | 2025 | Sunosi |
| Grifols USA, LLC | $41.68 | 2025 | Prolastin-C Liquid |
| Sunovion Pharmaceuticals INC. | $24.04 | 2019 | |
| Mylan Specialty L.P. | $19.40 | 2020 | |
| Amgen INC. | $16.82 | 2025 | Tezspire |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Verona Pharma, INC. | $16.78 | 2025 | Ohtuvayre |
| United Therapeutics Corporation | $16.12 | 2025 | Tyvaso |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonaid Aslam listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.